<DOC>
	<DOCNO>NCT02410213</DOCNO>
	<brief_summary>This Phase II , open-label , non-randomized , multi-center , single arm study characterize pharmacokinetic pharmacodynamics ( PK/PD ) profile Ferric Carboxymaltose dose pediatric subject IDA receive either 7.5 mg/kg 15 mg/kg dose Ferric Carboxymaltose .</brief_summary>
	<brief_title>A Study Characterize Pharmacokinetics Pharmacodynamics Profile Intravenous Ferric Carboxymaltose Pediatric Subjects 1-17 Years Old With Iron Deficiency Anemia ( IDA )</brief_title>
	<detailed_description>This Phase II , open-label , non-randomized , multi-center , single arm study characterize pharmacokinetic pharmacodynamics ( PK/PD ) profile Ferric Carboxymaltose dose pediatric subject IDA receive either 7.5 mg/kg 15 mg/kg dose Ferric Carboxymaltose .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female subject 1 17 year age assent participation his/her parent guardian willing able sign inform consent approve Independent Review Board / Ethics Committee . Screening TSAT &lt; 20 % Screening Hemoglobin &lt; 11 g/dL For subject receive erythropoietin stimulate agent ( ESA ) : stable ESA therapy ( +/ 20 % current dose ) &gt; 8 week prior qualify screen visit ESA dose product change anticipate length trial Known hypersensitivity reaction component Ferric Carboxymaltose . Subject previously randomize treat study clinical study Ferric Carboxymaltose ( FCM VIT45 ) . Body mass index ( BMI ) â‰¤ 5th percentile age ( see APPENDIX 2 ) Male Female subject 1 year age weigh &lt; 12kg . History acquire iron overload , hemochromatosis iron accumulation disorder . Chronic kidney disease subject hemodialysis . Screening Ferritin level &gt; 300ng/mL Subjects significant severe disease liver , hemopoietic system , cardiovascular system , psychiatric disorder condition opinion investigator may place subject add risk . Any active infection . Known positive hepatitis B antigen ( HBsAg ) hepatitis C viral antibody ( HCV ) evidence active hepatitis . Known positive HIV1/HIV2 antibody ( antiHIV ) . Anemia due reason iron deficiency ( i.e . hemoglobinopathy ) . Subjects treat vitamin B12 folic acid deficiency permit . Intravenous iron /or blood transfusion 4 week prior screen . Immunosuppressive therapy may lead anemia ( i.e . cyclophosphamide , azathioprine , mycophenolate mofetil ) . Note steroid therapy permit . Administration / use investigational product ( drug device ) within 30 day screen . Alcohol drug abuse within past six month . Female subject pregnant lactating , sexually active female childbearing potential willing use acceptable form contraceptive precaution study . Subject unable comply study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>